Have an account? Log in.
I don't have an account.
Corbus reports FDA alignment on the CRB-701 path, as analysts flag upside tied to the head and neck cancer opportunity and obesity pipeline.
https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-information-or-potential-signals-serious-risks-identified-fda
Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. See others' views on these stocks.
Wolfe Research analyst Kalpit Patel initiates coverage on Genmab (NASDAQ:GMAB) with a Outperform rating and announces Price Target of $32.
The Starter plan only unlocks analyses for the 25 stocks tracked over the past month. With the Compact plan, you get access to all stocks from Germany and the USA – with Premium, worldwide access.